Regeneron, Sanofi asthma drug data fails to excite investors

11 Sep by

Regeneron, Sanofi asthma drug data fails to excite investors

Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor expectations. The drug, which is approved for atopic dermatitis, met its two main goals in patients with uncontrolled, persistent asthma. At 52 weeks, dupilumab reduced severe asthma attacks by 46 percent in the overall population in the late-stage trial.

…Read the rest of this story

Source:: https://finance.yahoo.com/news/sanofi-regeneron-score-asthma-hit-063153351.html

By